Team 5

483 views

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
483
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • Health care centers non OTC drugs , accurate dose required
  • Team 5

    1. 1. Pluto®: The resistance-free generation<br />
    2. 2. Executive Summary<br />The purpose of this plan is to launch “Pluto, 2nd G TKI which is indicated as a single agent for the treatment of adult CML patients.<br />
    3. 3. Executive Summary<br />
    4. 4. Strategic Planning Roadmap<br />
    5. 5. I. Environmental Analysis<br />SWOT Analysis<br />
    6. 6. NOVARTIS<br />
    7. 7. PLUTO®<br />
    8. 8. CONCLUSION<br />We can focus on the following points in our strategic plan:<br />
    9. 9. II. Strategic Objectives<br />A. Mission Statement<br />As a leading private pharmaceutical company in the Egyptian market, we are committed to develop and maintain our leading position in the pharmaceutical industry in a patient-centered environment. We strive to attain the highest health standard for our patients, regardless of their cultural or social differences.<br />
    10. 10. B. Strategic Objectives<br />Qualitative Objective<br />Customer satisfaction: 1st choice for prescribing doctors, oncologists, haematologists, health care organizations and health insurance companies.<br />Quantitative Objectives<br />To be the 1st choice for treatment of at least 60% of imatinib-resistant and intolerant cases, with intention to increase to 80% within the next 5 years.<br />To obtain a Return on Investment of at least 6:1 by the end of 5 years.<br />
    11. 11. III. Strategic Formulation<br />A. Product of Service Offerings<br />Pluto: <br />2nd generation oral tyrosine kinase inhibitor<br />Low SE and cost<br />Rapid and durable response <br />Ttt of Ph+ CML adult patients resistant and intolerant to at least one prior therapy <br />
    12. 12. B. Strategic Scope<br />1High2Low<br />(↑ efficacy , ↓SE &$)<br />
    13. 13. C. Marketing Mix<br />Pluto ®<br />1500 LE/month<br />Hematologists<br />oncologists<br />
    14. 14. IV. Strategy Implementation and Evaluation<br />Resources:<br />almost 2,000,000 LE for implementation support and advertisement.<br />Assumptions:<br />Resistance cases for imatinib represent 20% of all leukemic patients.<br />Adverse events occurred in 20% of this population.<br />
    15. 15. A. Financial Plan<br />
    16. 16. B. Action Plan<br />
    17. 17.
    18. 18.
    19. 19. C. KPI<br />
    20. 20. Pilot study<br />This methodology trial was applied to one institute.<br />- Phase I:<br /> Plan:<br />Place of application: spicialinsttitutes in Cairo, Giza and Alex<br />Time of application: first 2 years<br />- Phase II:<br />Review strategy.<br /><ul><li>Phase III:</li></ul>Finalize strategy and implement.<br />Evaluate & verify results.<br />Phase VI:<br />Results: <br />1ry result: doctors prescribed these drugs to the appropriate patients (resistant to Mirac).<br />2ry result: patients with adverse events are switched to Pluto.<br />
    21. 21.
    22. 22. Feedback loop:<br />Measure actual performance<br />Compare to standards<br />Establish control standard<br />OK<br />Not OK<br />Trouble shooting<br />Diagnose the cause<br />Remedy the cause<br />Identify the problem<br />
    23. 23. Thank you!<br />

    ×